COGT Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.511

+467.31%

-0.488

-6.09%

-0.502

-5.35%

Estimates Revision

The market is revising No Change the revenue expectations for Cogent Biosciences, Inc. (COGT) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 132.80%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+3.18%

In Past 3 Month

Stock Price

Go Up

+132.80%

In Past 3 Month

11 Analyst Rating

Wall Street analysts forecast COGT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COGT is 42.50 USD with a low forecast of 20.00 USD and a high forecast of 65.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

2 Hold

0 Sell

Strong Buy

Current: 0.000

Low

20.00

Averages

42.50

High

65.00

Current: 0.000

Low

20.00

Averages

42.50

High

65.00

H.C. Wainwright

Buy

maintain

$50 -> $52

2026-01-06

New

Reason

H.C. Wainwright

Price Target

$50 -> $52

2026-01-06

New

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Cogent Biosciences to $52 from $50 and keeps a Buy rating on the shares. The firm sees an "uneventful" FDA review process for bezuclastinib in non-advanced mastocytosis.

JPMorgan

NULL -> Overweight

maintain

$65 -> $67

2025-12-19

Reason

JPMorgan

Price Target

$65 -> $67

2025-12-19

maintain

NULL -> Overweight

Reason

JPMorgan raised the firm's price target on Cogent Biosciences to $67 from $65 and keeps an Overweight rating on the shares. The firm updated models in the smid-cap biotechnology group.

Jefferies

Buy

maintain

$45 -> $48

2025-12-08

Reason

Jefferies

Price Target

$45 -> $48

2025-12-08

maintain

Buy

Reason

Jefferies raised the firm's price target on Cogent Biosciences to $48 from $45 and keeps a Buy rating on the shares. Results from the APEX trial showed a 49% overall response rate for bezuclastinib, supporting its potential as a preferred therapy in Advanced Systemic Mastocytosis given its differentiated profile, the analyst tells investors in a research note. In SUMMIT, week-48 data demonstrated deeper clinical responses and strong disease-modifying activity, and with three successful pivotal readouts this year, Cogent appears positioned to pursue an opportunity exceeding $7B, Jefferies says.

H.C. Wainwright

NULL -> Buy

upgrade

$21 -> $50

2025-11-13

Reason

H.C. Wainwright

Price Target

$21 -> $50

2025-11-13

upgrade

NULL -> Buy

Reason

H.C. Wainwright raised the firm's price target on Cogent Biosciences to $50 from $21 and keeps a Buy rating on the shares. The firm believes bezuclastinib plus sunitinib is likely to become the standard-of-care in second-line gastrointestinal stromal tumors based on the PEAK trial results.

Baird

Neutral

maintain

$14 -> $34

2025-11-11

Reason

Baird

Price Target

$14 -> $34

2025-11-11

maintain

Neutral

Reason

Baird raised the firm's price target on Cogent Biosciences to $34 from $14 and keeps a Neutral rating on the shares. The firm updated its model following positive Phase 3 PEAK data for Bezu/Sunitnib combo in 2L GIST.

Wedbush

David Nierengarten

Neutral -> Outperform

upgrade

$13 -> $38

2025-11-10

Reason

Wedbush

David Nierengarten

Price Target

$13 -> $38

2025-11-10

upgrade

Neutral -> Outperform

Reason

Wedbush analyst David Nierengarten upgraded Cogent Biosciences to Outperform from Neutral with a price target of $38, up from $13.

Valuation Metrics

The current forward P/E ratio for Cogent Biosciences Inc (COGT.O) is -17.41, compared to its 5-year average forward P/E of -4.93. For a more detailed relative valuation and DCF analysis to assess Cogent Biosciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.93

Current PE

-17.41

Overvalued PE

-2.09

Undervalued PE

-7.78

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.35

Current EV/EBITDA

-17.68

Overvalued EV/EBITDA

1.39

Undervalued EV/EBITDA

-6.09

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

32659.27

Current PS

886.56

Overvalued PS

226325.93

Undervalued PS

-161007.39

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 2828.69% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

COGT News & Events

Events Timeline

No data

News

5.0

01-02Barron's

Cogent Biosciences Shares Surge in 2025 Amid Executive Stock Sales

9.5

2025-12-31NASDAQ.COM

Palvella Therapeutics Stock Soars to $114.69 Following Pipeline Developments

9.0

2025-12-30Globenewswire

Cogent Submits NDA for Bezuclastinib in NonAdvanced Systemic Mastocytosis

People Also Watch

Frequently Asked Questions

What is Cogent Biosciences Inc (COGT) stock price today?

The current price of COGT is 36.27 USD — it has increased 4.28 % in the last trading day.

What is Cogent Biosciences Inc (COGT)'s business?

Cogent Biosciences, Inc. is a biotechnology company. The Company is focused on developing precision therapies for genetically defined diseases. The Company’s clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2 and PI3Kα. SUMMIT is its randomized, global, multicenter, double-blind, placebo-controlled, multi-part Phase II clinical trial for patients with Non-AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.

What is the price predicton of COGT Stock?

What is Cogent Biosciences Inc (COGT)'s revenue for the last quarter?

Cogent Biosciences Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Cogent Biosciences Inc (COGT)'s earnings per share (EPS) for the last quarter?

Cogent Biosciences Inc. EPS for the last quarter amounts to -0.59 USD, decreased -7.81 % YoY.

What changes have occurred in the market's expectations for Cogent Biosciences Inc (COGT)'s fundamentals?

How many employees does Cogent Biosciences Inc (COGT). have?

Cogent Biosciences Inc (COGT) has 205 emplpoyees as of January 08 2026.

What is Cogent Biosciences Inc (COGT) market cap?

Today COGT has the market capitalization of 5.57B USD.